경도의 안구 건조증에서 레스타시스®의 임상 효과 = Cinical Effect of Restasis® Eye Drops in Mild Dry Eye Syndrome

국문 초록 (Abstract)

목적: 경도의 안구 건조증 환자에 레스타시스Ⓡ(RestasisⓇ, topical 0.05% cyclosporine, Allergan, USA) 사용 후 임상 효과에 관하여
알아보았다.
대상과 방법: 경도의 안구 건조증으로 진단받고, 레스타시스Ⓡ를 사용한 23명 46안을 대상으로 OSDI 설문 조사, BUT, Shirmer test를 통한
점수를 치료 전, 치료 후 1개월, 2개월, 3개월, 6개월에 걸쳐 비교하였다.
결과: 대상군 중 남자가 8명, 여자가 15명이었고, 평균 나이는 50.5세였다. 치료 전 OSDI (Ocular Surface Disease Index) 점수의 평균
값은 32.3이었고, BUT, shirmer test의 평균 값은 5.3초, 8.1 mm이었다. 치료 후 6개월째 OSDI, BUT, Shirmer test의 평균 값은 각각
22.9, 8.1초, 12.1 mm이었다. 주관적 지표인 OSDI 설문조사의 경우 치료 2개월부터 유의한 호전을 보였고(p=0.003), 객관적 지표인
BUT, Shirmer test의 경우 치료 시작 3개월째부터 유의한 호전이 나타났다(p=0.03, p=0.04).
결론: 경도의 안구 건조증 환자에 있어서도 레스타시스Ⓡ로 치료하면 임상 증상이 호전됨을 알 수 있었다.

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate changes in tear secretion and symptoms in patients with mild dry eye syndrome after using RestasisⓇ.
Methods: From patients diagnosed with mild dry eye syndrome, RestasisⓇ was administered to 46 eyes of 23 patients. The clinical
parameters and symptoms were checked over a period of six months. The clinical parameters evaluated were the symptoms of
dry eye syndrome using an OSDI scoring scale, the Schirmer test, and tear break-up time.
Results: Eight male patients and 15 female patients were included in the study. The mean age was 50.5 years. Before treatment,
the values for the OSDI score, BUT, and Schirmer test were 32.3, 5.3 mm, and 8.1 seconds, respectively. After treatment, the OSDI
score, BUT, and Schirmer test were 22.9, 8.1 mm, and 12.1 seconds at six months, respectively. The subjective parameter (OSDI score)
improved two months after treatment (p=0.003), and the objective parameters (BUT, Schirmer test) improved three months after
treatment (p=0.03, p=0.04, respectively).
Conclusions: In the present study, RestasisⓇ increased tear secretion and improved clinical symptoms of patients with mild dry eye.

참고문헌 (Reference)

1 변여주, "다양한 안표면질환에 대한 0.05퍼센트 싸이클로스포린 점안제의 단기 효과" 대한안과학회 49 (49): 401-408, 2008

2 Sall K, "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease" 107 : 631-639, 2000

3 Perry HD, "Topical 0.05% cyclosporine A in the treatment of the dry eye" 5 : 2099-2107, 2004

4 Hong S, "Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren’s syndrome" 23 : 78-82, 2007

5 Laibovitz RA, "Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca" 12 : 315-323, 1993

6 Barber LD, "Phase III safty evaluation of cyclosporine 0.1% ophthalmic emulsion Administered twice daily to dry eye disease patients for up to 3 years" 112 : 1790-1794, 2005

7 Dogru M, "New insights into the diagnosis and treatment of dry eye" 2 : 59-75, 2004

8 Wilson SE, "Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment" 114 : 76-79, 2007

9 Stern ME, "Inflammation in dry eye" 2 : 124-130, 2004

10 Borel JF, "In vivo pharmacological effects of cyclosporin and some analogues" 35 : 115-246, 1996

11 Brignole F, "Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A" 42 : 90-95, 2001

12 Perry HD, "Evaluation of topical cyclosporine for the treatment of dry eye disease" 126 : 1046-1050, 2008

13 Stevenson D, "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease" 107 : 967-974, 2000

14 Power WJ, "Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjongren’s syndrome" 12 : 507-511, 1993

15 O’Brien PD, "Dry eye: Diagnosis and current treatment strategies" 4 : 314-319, 2004

16 Kunert KS, "Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes" 118 : 1489-1496, 2000

17 Wilson SE, "Agrement of physician treatment practices with the international task force guidelines for diagnosis and treat ment of dry eye disease" 26 : 284-289, 2007